HSCT for CGD with no overt infection/inflammation
| Characteristic . | Data . |
|---|---|
| Patient no.3-150 | 17-27 |
| CGD type | 5 X-CGD; 4 gp91phox; 2 unknown |
| Age, y (median) | 0.8-14 (7) |
| Sex | 10 M; 1 F |
| Sex of donor | 8 F3-151; 3 M3-152 |
| Marrow MNCs infused per kg, × 108 (median) | 2.1-9.5 (4.7) |
| Conditioning | 9 Bu, Cy; 1 Bu, Cy, TNI; 1 Bu, Cy, TT, ATG |
| Risk factors | 7 none; 4 Aspergillus pneumonia (history) |
| Outcome | 1 GVHD II; all alive and well |
| Myeloid engraftment, extent of hemopoiesis (median) | 0.3-4 y, all full (2 y) |
| Characteristic . | Data . |
|---|---|
| Patient no.3-150 | 17-27 |
| CGD type | 5 X-CGD; 4 gp91phox; 2 unknown |
| Age, y (median) | 0.8-14 (7) |
| Sex | 10 M; 1 F |
| Sex of donor | 8 F3-151; 3 M3-152 |
| Marrow MNCs infused per kg, × 108 (median) | 2.1-9.5 (4.7) |
| Conditioning | 9 Bu, Cy; 1 Bu, Cy, TNI; 1 Bu, Cy, TT, ATG |
| Risk factors | 7 none; 4 Aspergillus pneumonia (history) |
| Outcome | 1 GVHD II; all alive and well |
| Myeloid engraftment, extent of hemopoiesis (median) | 0.3-4 y, all full (2 y) |
TNI indicates total node irradiation; and TT, thiothepa. For other abbreviations see Table 1 footnote.
See Zintl et al,9 Hobbs et al,10Calviño et al.11
Includes 2 heterozygous carriers of X-CGD.
Includes 2 matched unrelated donors (1 mixed leukocyte culture negative; one molecularly matched).